Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Combined Nicotinic Acid and Statin Treatment Reduces Atherosclerosis

By LabMedica International staff writers
Posted on 20 Nov 2009
A recent study showed that combining statin treatment to lower cholesterol levels with nicotinic acid (niacin) to raise the level of HDL (high density lipoprotein) cholesterol improved the condition of patients with established cardiovascular disease.

Investigators at Oxford University (United Kingdom) performed a double-blind, randomized, placebo-controlled study of two grams of daily modified-release nicotinic acid added to statin therapy in 71 patients with low HDL cholesterol (less than 40 mg/dl) and either type II diabetes with coronary heart disease; or carotid/peripheral atherosclerosis. More...
The primary end point of the study was the determination after one year of the change in carotid artery wall area, quantified by MRI (magnetic resonance imaging).

The investigators reported in the November 3, 2009, issue of the Journal of the American College of Cardiology that the statin-nicotinic acid regimen increased HDL cholesterol by 23% and decreased LDL (low density lipoprotein) cholesterol by 19%. At 12 months, the carotid wall area was significantly reduced compared with placebo (decreased by an average of 1.1 mm2 for those on the drug combination as opposed to an average increase in the carotid artery wall of 1.2 mm2 for those receiving a placebo).

"This is the first clear evidence that a therapy to raise levels of good cholesterol (HDL) when taken alongside statins can have a beneficial effect," said senior author Dr Robin Choudhury, professor of cardiovascular medicine at the University of Oxford. "Using MRI scans, we have shown a reduction in the size of artery walls in patients after a year of treatment with nicotinic acid. Our imaging study has identified this as a very promising new prospect for treatment, and if the findings are borne out in ongoing larger studies this could benefit large numbers of people worldwide."

"Our results are very encouraging in that they have shown a very definite potential benefit, and will certainly increase the great interest in the large outcome studies that are due to report in the next couple of years," said Dr. Choudhury. 'For years we had always been taught that atherosclerosis was a relentless progressive disease. It is exciting to see a regression in established atherosclerosis."


Related Links:
Oxford University




Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.